ORAL PIRITREXIM, AND EFFECTIVE TREATMENT FOR METASTATIC UROTHELIAL CANCER

被引:40
|
作者
DEWIT, R
KAYE, SB
ROBERTS, JT
STOTER, G
SCOTT, J
VERWEIJ, J
机构
[1] WESTERN INFIRM & ASSOCIATED HOSP,BEATSON ONCOL CTR,GLASGOW G11 6NT,SCOTLAND
[2] NEWCASTLE GEN HOSP,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND
[3] WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND
基金
英国惠康基金;
关键词
D O I
10.1038/bjc.1993.71
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Piritrexim is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells rapidly by passive diffusion, cannot be polyglutamated, and is as effective as methotrexate in inhibiting DHFR. Bioavailability after oral dosing is approximately 75%. We performed a phase II study with oral piritrexim in non-chemotherapy pretreated patients with metastatic urothelial cancer. Thirty-three patients were treated with 25 mg three times daily for 5 consecutive days, repeated weekly, with provision for dose escalation or reduction according to the toxicity observed. Of 29 evaluable patients, one patient achieved a complete response of 19 + weeks duration, and ten patients achieved a partial response with a median duration of 22 weeks (range 16-48), for a total response rate of 38%. Piritrexim was generally well tolerated, with myelosuppression as the major toxicity, that frequently required dose modification. We conclude that piritrexim appears to be an active agent in patients with metastatic urothelial cancer when administered as a 5-day, low-dose oral schedule. It would be attractive to investigate the combination of piritrexim and cisplatin.
引用
收藏
页码:388 / 390
页数:3
相关论文
共 50 条
  • [1] A PHASE-II AND PHARMACOKINETIC STUDY WITH ORAL PIRITREXIM FOR METASTATIC BREAST-CANCER
    DEVRIES, EGE
    GIETEMA, JA
    WORKMAN, P
    SCOTT, JE
    CRAWSHAW, A
    DOBBS, HJ
    DENNIS, I
    MULDER, NH
    SLEIJFER, DT
    WILLEMSE, PHB
    BRITISH JOURNAL OF CANCER, 1993, 68 (03) : 641 - 644
  • [2] Updates in the Treatment of Metastatic Urothelial Cancer
    Flaig, Thomas W.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
  • [3] Treatment of Metastatic Urothelial Cancer in 2018
    Bellmunt, Joaquim
    Rodriguez-Vida, Alejo
    JAMA ONCOLOGY, 2019, 5 (06) : 904 - 905
  • [4] Antiangiogenic treatment in metastatic urothelial cancer
    Galsky, Matthew D.
    LANCET ONCOLOGY, 2012, 13 (08): : 748 - 749
  • [5] The evolving treatment landscape of metastatic urothelial cancer
    Roviello, Giandomenico
    Santoni, Matteo
    Sonpavde, Guru P.
    Catalano, Martina
    NATURE REVIEWS UROLOGY, 2024, 21 (10) : 580 - 592
  • [6] Emerging agents for the treatment of metastatic urothelial cancer
    Kwon, Whi-An
    Seo, Ho Kyung
    INVESTIGATIVE AND CLINICAL UROLOGY, 2021, 62 (03) : 243 - 255
  • [7] ORAL PIRITREXIM IN ADVANCED BLADDER-CANCER - AN EFFECTIVE DRUG AFTER PROGRESSION ON MVAC CHEMOTHERAPY
    FEUN, LG
    SAVARAJ, N
    BENEDETTO, P
    WALDMAN, S
    COLLIER, M
    CLENDENNIN, NJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (05): : 448 - 451
  • [8] Towards effective adjuvant treatment for urothelial cancer
    Siefker-Radtke, Arlene O.
    Gao, Jianjun
    LANCET ONCOLOGY, 2015, 16 (01): : 9 - 10
  • [9] Biomarkers determining treatment tactics in metastatic urothelial cancer
    Grivtsova, L. Yu.
    Karyakin, O. B.
    Syadrin, M. G.
    Samborsky, S. M.
    Ivanov, S. A.
    Kaprin, A. D.
    ONKOUROLOGIYA, 2023, 19 (02): : 111 - 126
  • [10] Metastatic Urothelial Cancer: a rapidly changing treatment landscape
    Stecca, Carlos
    Abdeljalil, Osama
    Sridhar, Srikala S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13